Core Viewpoint - A major shareholder of Jiukang Biological (stock code: 300406) plans to reduce their stake in the company by up to 221.42 million shares, representing 0.38% of the total share capital [1] Group 1 - The shareholder, Zhou Xiaoyan, currently holds 30.7696 million shares, which accounts for 5.25% of the company's total share capital [1] - The reduction will be executed through centralized bidding or block trading methods [1]

Core Viewpoint - The major shareholder Zhou Xiaoyan of Jiukang Bio plans to reduce their stake in the company by selling up to 2.2142 million shares between December 3, 2025, and March 2, 2026, which represents 0.38% of the total share capital and voting shares [1] Summary by Categories - **Shareholder Information** - Zhou Xiaoyan holds 30.7696 million shares, accounting for 5.25% of the total share capital and 5.28% of the voting shares [1] - **Reduction Plan** - The planned reduction will occur through centralized bidding and/or block trading methods [1] - The maximum number of shares to be sold is 2.2142 million, which is 0.38% of the total share capital and voting shares [1]

证券代码：300406 证券简称：九强生物 公告编号：2025-102 债券代码：123150 债券简称：九强转债 北京九强生物技术股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有北京九强生物技术股份有限公司(以下简称"公司"或"九强生物") 股份30,769,636股（占公司总股本比例为5.25%，占公司有表决权股份比例 为5.28%，"公司有表决权股份"为截至2025年11月10日收盘时总股本剔除 公司回购专用账户中的股份数量，下同）的自然人股东ZHOU XIAOYAN女士计 划自本公告披露之日起十五个交易日后的三个月内以集中竞价和/或大宗交 易方式减持本公司股份，计划减持数量不超过2,214,173股（占公司总股本 比例为0.38%，占公司有表决权股份比例为0.38%）。 公司于近日收到持股5%以上自然人股东ZHOU XIAOYAN女士出具的《股份 减持计划告知函》，现将有关情况公告如下： | 股东名称 | | 任职情况 | 持股数量（股） | 占公司总股 本比例（%） | 占公司有表决 权股份比例 （%） | 持有有限售条 件股份数量 （股） | 持有 ...

Group 1 - The sixth Panoramic Investor Relations Gold Award was recently announced, with Jiukang Biological (300406.SZ) winning the "Outstanding IR Team" award and its Secretary Wang Jianmin receiving the "Outstanding Secretary" award [1] - The evaluation process involved self-nomination, public online voting, professional index scoring, and expert review, covering thousands of A-share companies, establishing itself as a benchmark in the capital market IR field [1] - The award focuses on six innovative dimensions: digital investor relations, response to small investors' concerns, institutional attention, market value management, shareholder returns, and ESG value dissemination, marking Jiukang Biological's IR management as recognized by the capital market [1] Group 2 - Jiukang Biological has been a leader in the domestic in vitro diagnostic industry for 20 years, developing a diversified and high-quality diagnostic testing platform [2] - The company has established various biochemical research and development platforms, including chemical methods, enzyme methods, and immunoassay techniques, and has high-level R&D capabilities in liquid blood coagulation and blood type testing [2] - Jiukang Biological's subsidiary, Maxin Biological, focuses on core technologies in pathological diagnosis and explores innovative technologies such as companion diagnostics and AI in pathology, aiming for the integrated development of six technical platforms [2]

Core Viewpoint - Jiukang Bio (300406) has recently received a medical device registration certificate from the Beijing Drug Administration for two new products, indicating a significant advancement in its product offerings [1] Product Registration - The first product is the "Heparin Binding Protein Assay Kit (Magnetic Microparticle Chemiluminescent Immunoassay)," which is designed for the in vitro quantitative measurement of heparin binding protein (HBP) levels in human plasma [1] - The second product is the "Fully Automatic Biochemical Analyzer (Models: Gc2000, Gc2400)," which is intended to be used in conjunction with compatible reagents for qualitative and quantitative analysis of substances in human samples [1]

Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates from the Beijing Drug Administration for two products, indicating a significant step in its product development and regulatory approval process [1] Group 1 - The company has obtained registration for the Heparin Binding Protein Assay Kit, which utilizes magnetic microparticle chemiluminescent immunoassay technology [1] - The company has also received approval for the fully automated biochemical analyzer, models Gc2000 and Gc2400, expanding its product offerings in the medical device sector [1]

Core Viewpoint - The company, Jiukang Biological, has received medical device registration certificates from the Beijing Drug Administration for two products, indicating a significant regulatory milestone for the company [1] Group 1: Product Information - The registered products include the Heparin Binding Protein Assay Kit (using magnetic microparticle chemiluminescent immunoassay) and the fully automatic biochemical analyzer (models Gc2000 and Gc2400) [1]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-101 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 特此公告。 北京九强生物技术股份有限公司 董事会 2025年11月3日 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 肝素结合蛋白测定 试剂盒（磁微粒化学 发光免疫分析法） | 京 械 注 准 20252400893 | Ⅱ | 自批准之日起有效期 至 2030 年 10 月 29 日 | 本试剂盒用于体外定量 测定人血浆中肝素结合 蛋白（HBP）的含量。 | | 2 | 全自动生化分析仪 （型号：Gc 2000、 Gc 2400） | 京 械 注 准 20252220895 | Ⅱ | 自批准之日起有效期 至 2030 年 10 月 29 日 | 与适配试剂配合 ...

Group 1 - Company Jiukang Bio (SZ 300406) announced on October 31 that it has received three patent certificates from the National Intellectual Property Administration of the People's Republic of China, including "A Digoxin Detection Kit" and "Fully Automatic Coagulation Analyzer" [1] - For the year 2024, Jiukang Bio's revenue composition is 100% from the healthcare sector [1] - As of the report date, Jiukang Bio has a market capitalization of 8 billion yuan [1]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 北京九强生物技术股份有限公司（以下简称"九强生物"或"公司"）于近 期收到中华人民共和国国家知识产权局颁发的 3 项专利证书，具体情况如下： | 序号 | 专利号 | 专利名称 | 专利权人 | 专利类型 | 申请日期 | 授权日期 | 证书号 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | ZL2023108 11210.8 | 一种洋地黄毒苷检 测试剂盒 | 九强生物 | 发明 | 2019.12.27 | 2025.10.24第 | 8395149 | 号 | | 2 | ZL2025300 87771.8 | 全自动凝血分析仪 （MDC7600 系列） | 九强生物 | 外观设计 | 2025.02.27 | 2025.10.21第 | 9572806 | 号 | | 3 | ZL2025300 87772.2 | 全自动凝血分析仪 （MDC3600 系列） | 九强生物 | 外观设计 | 2025.02.27 | 2025 ...